Reviewing Biofrontera AG (BFRA)’s and Its Competitors results

We are contrasting Biofrontera AG (NASDAQ:BFRA) and its peers on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. They are Biotechnology companies, competing one another.

Insider and Institutional Ownership

Biofrontera AG has 2.04% of its shares held by institutional investors versus an average of 53.20% institutional ownership for its peers. On other hand Biofrontera AG has 0.04% of its shares held by company insiders versus an average of 8.45% insiders ownership for its competitors.


On first table we have Biofrontera AG and its competitors’ return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Biofrontera AG 95,817,843.87% 0.00% 0.00%
Industry Average 812.10% 105.95% 28.39%

Valuation & Earnings

The following data compares Biofrontera AG and its competitors’ top-line revenue, net income and valuation.

Net Income Gross Revenue Price/Earnings Ratio
Biofrontera AG 10.31M 11 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Recommendations

Table 3 provides breakdown of recent ratings for Biofrontera AG and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Biofrontera AG 0 0 0 0.00
Industry Average 1.10 1.78 2.38 2.81

The peers have a potential upside of 168.19%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Biofrontera AG and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Biofrontera AG -5.81% -11.18% 28.16% 14% 2.71% 32.89%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year Biofrontera AG was less bullish than its rivals.


Biofrontera AG does not pay a dividend.


Biofrontera AG’s rivals show that they’re better in 4 of the 4 indicators compared to the company itself.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.